Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.66 |
| ▸ | HTR1A | P08908 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7210648 | 0.89 | SIGMAR1 (0.58) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL15383624 | 0.84 | SIGMAR1 (0.48) | SIGMAR1HTR1A | |
| SCHEMBL30350966 | 0.84 | SIGMAR1 (0.66) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL25223898 | 0.84 | SIGMAR1 (0.48) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL7855443 | 0.83 | SIGMAR1 (0.63) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL4447104 | 0.82 | DRD2 (0.58) | HTR1ADRD2 | |
| SCHEMBL9766008 | 0.80 | SIGMAR1 (0.60) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL9400960 | 0.80 | CYP2D6 (0.54) | SIGMAR1HTR1ADRD2 | |
| SCHEMBL13532670 | 0.80 | SIGMAR1 (0.60) | SIGMAR1HTR1AKDM4ECYP1A2GAA | |
| SCHEMBL9765984 | 0.80 | SIGMAR1 (1.00) | SIGMAR1HTR1AKDM4ECYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432958-B1 | FOR THERAPY AND PROPHYLAXIS OF NEUROPSYCHOLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA, MANIA, DEMENTIA, DEPRESSION, ANXIETY, COMPULSIVE BEHAVIOR, SUBSTANCE ABUSE, MOTOR DISORDERS AND MOTION DISORDERS RELATED TO USE OF NEUROLEPTIC AGENT | NEUROGEN CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-05-16 | — | — | US | disclosed |
| US-6284759-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-09-04 | — | — | US | disclosed |
| EP-1117663-A2 | 2-PIPERAZINO ALKYLAMINO BENZOAZOLE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018767-A9 | 2-PIPERAZINO ALKYLAMINO BENZOAZOLE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000018767-A2 | 2-PIPERAZINO ALKYLAMINO BENZOAZOLE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | CHRNA7, HTR7, OPRD1 | SIGMAR1 5/4885HTR1A 16/4885KDM4E 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.